JP5740714B2 - クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 - Google Patents

クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 Download PDF

Info

Publication number
JP5740714B2
JP5740714B2 JP2011550652A JP2011550652A JP5740714B2 JP 5740714 B2 JP5740714 B2 JP 5740714B2 JP 2011550652 A JP2011550652 A JP 2011550652A JP 2011550652 A JP2011550652 A JP 2011550652A JP 5740714 B2 JP5740714 B2 JP 5740714B2
Authority
JP
Japan
Prior art keywords
toxin
difficile
antibody
sheep
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011550652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518624A (ja
JP2012518624A5 (enExample
Inventor
ショーン，クリフォード
ランドン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micropharm Ltd
Original Assignee
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0902851A external-priority patent/GB0902851D0/en
Priority claimed from GB0916153A external-priority patent/GB0916153D0/en
Application filed by Micropharm Ltd filed Critical Micropharm Ltd
Publication of JP2012518624A publication Critical patent/JP2012518624A/ja
Publication of JP2012518624A5 publication Critical patent/JP2012518624A5/ja
Application granted granted Critical
Publication of JP5740714B2 publication Critical patent/JP5740714B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2011550652A 2009-02-20 2010-02-19 クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 Active JP5740714B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0902851.5 2009-02-20
GB0902851A GB0902851D0 (en) 2009-02-20 2009-02-20 Antibodies to clostridium difficile toxins
GB0916153A GB0916153D0 (en) 2009-09-15 2009-09-15 Antibodies to clostridium difficile toxins
GB0916153.0 2009-09-15
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins

Publications (3)

Publication Number Publication Date
JP2012518624A JP2012518624A (ja) 2012-08-16
JP2012518624A5 JP2012518624A5 (enExample) 2013-03-07
JP5740714B2 true JP5740714B2 (ja) 2015-06-24

Family

ID=42109880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550652A Active JP5740714B2 (ja) 2009-02-20 2010-02-19 クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体

Country Status (7)

Country Link
US (2) US8709428B2 (enExample)
EP (1) EP2405940B1 (enExample)
JP (1) JP5740714B2 (enExample)
CN (1) CN102365097A (enExample)
AU (1) AU2010215275B2 (enExample)
CA (1) CA2752815A1 (enExample)
WO (1) WO2010094970A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
MX391236B (es) * 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
GB201110712D0 (en) 2011-06-23 2011-08-10 Univ Ulster Diagnostic methods
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
RU2628305C2 (ru) 2012-03-02 2017-08-15 Регенерон Фармасьютиказ, Инк. Человеческие антитела к токсинам clostridium difficile
EP2921502A4 (en) 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2016501877A (ja) * 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
CN105555309A (zh) * 2013-04-19 2016-05-04 英穆伦有限公司 治疗和/或预防艰难梭菌相关疾病的方法和组合物
CA2910200A1 (en) 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
WO2015150493A1 (en) * 2014-04-01 2015-10-08 Institut Pasteur Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
AU702405B2 (en) 1994-09-06 1999-02-18 Immucell Corporation Therapeutic treatment of clostridium difficile associated diseases
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE69829400T2 (de) * 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DK1766093T3 (da) * 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
EP1833510A4 (en) 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
JP2012518624A (ja) 2012-08-16
US20120121607A1 (en) 2012-05-17
AU2010215275B2 (en) 2016-03-31
EP2405940A1 (en) 2012-01-18
CA2752815A1 (en) 2010-08-26
EP2405940B1 (en) 2021-08-04
US8709428B2 (en) 2014-04-29
US20150010580A1 (en) 2015-01-08
CN102365097A (zh) 2012-02-29
WO2010094970A1 (en) 2010-08-26
AU2010215275A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
JP5740714B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
US11447543B2 (en) Antibodies to S. aureus surface determinants
JP4904163B2 (ja) クロストリジウムディフィシル疾患に対する受動免疫感作
AU688763B2 (en) (Clostridial) toxin disease therapy
CA2307331C (en) Passive immunization against clostridium difficile disease
US20150093389A1 (en) Clostridium difficile antigens
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
TW201332568A (zh) 對抗表現碳青黴烯酶（ｃａｒｂａｐｅｎｅｍａｓｅ）之細菌之免疫組合物及方法
Osek et al. Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera
Batista et al. Immunogenicity and in vitro and in vivo protective effects of antibodies targeting a recombinant form of the Streptococcus mutans P1 surface protein
EP1687029A1 (en) Neutralizing human antibodies to anthrax toxin generated by recall technology
KR0180991B1 (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
Islam et al. Rationally designed minimized TbpB confers broad protection against meningococcal infection
HK1099198B (en) Passive immunization against clostridium difficile disease
HK1165269A (en) Passive immunization against clostridium difficile disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140519

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150408

R150 Certificate of patent or registration of utility model

Ref document number: 5740714

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250